VEGF抗体说明书
时间：2012-05-07 阅读：10699
VEGF单克隆抗体 100ul 2000元
VEGF，即vascular endothelial growth factor，也称VEGFA或VEGF-A，中文名为血管内皮生长因子，是一种可以强烈诱导血管生长的因子，在血管过程中起重要作用。肿瘤细胞在低氧（hypoxia）情况下可以分泌VEGF。VEGF的7种isoform是VEGF mRNA可变剪接（alternative splicing）的结果。zui常见的VEGF的isoform包括VEGF 121，VEGF 165，VEGF 189（相当于VEGF f、VEGF d和VEGF b）。VEGF的表达水平和肿瘤内的血管生长情况呈正相关，并且和肿瘤的转移风险呈正相关。VEGF可以促进内皮细胞增殖，促进细胞迁移，并抑制细胞凋亡。抑制VEGF信号转导可以抑制多种肿瘤的发生和发展。VEGF可以形成同源二聚体，可以和其受体VEGFR1/Flt-1和VEGFR2/Kdr，以及heparan sulfate和肝素相结合。VEGF-165和VEGF-145可以和Neuropilin-1相结合。
| |
BACKGROUND
The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described. These include fibroblast growth factors （FGFs）, plaet derived growth factor （PDGF） and vascular endothelial growth factor （VEGF）. VEGF is a dimeric glycoprotein with structural homology to PDGF. Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor in vivo because the expression pattern of VEGF is consistent with a role in embryonic angiogenesis. VEGF mRNA is formed in some primary tumors, VEGF is produced by tumor cell lines in vitro and VEGF mitogenic activity appears to be restricted to endothelial cells. A member of the PDGF receptor family, Flt, has been identified as a high-affinity receptor for VEGF.
REFERENCES
1. Folkman, J., et al. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61.
2. Conn, G., et al. 1990. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. Proc. Natl. Acad. Sci. USA
87: 1323-1327.
3. Tischer, E., et al. 1991. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.
J. Biol. Chem. 266: 11947-11954.
4. Ferrara, N., et al. 1991. The vascular endothelial growth factor family of polypeptides. J. Cell. Biochem. 47: 211-218.
5. Breier, G., et al. 1992. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114: 521-532.
6. Berse, B., et al. 1992. Vascular permeability factor （vascular endothelial growth factor） gene is expressed differentially in normal tissues, macro-phages and tumors. Mol. Biol. Cell 3: 211-220.
7. Plate, K.H., et al. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848.
CHROMOSOMAL LOCATION
Genetic locus: VEGFA （human） mapping to 6p21.1; Vegfa （mouse） mapping to 17 C.
SOURCE
VEGF （VG-1） is a mouse monoclonal antibody raised against recombinant VEGF189 protein.
PRODUCT
Each vial contains 200 μg IgG1 in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.
RESEARCH USE
For research use only, not for use in diagnostic procedures.
APPLICATIONS
VEGF （VG-1） is recommended for detection of the 189, 165 and 121 amino acid splice variants of VEGF of mouse, rat, human and dog origin by Western Blotting （starting dilution 1:200, dilution range 1:100-1:1000）, immunoprecipitation [1-2 μg per 100-500 μg of total protein （1 ml of cell lysate）], immunofluorescence （starting dilution 1:50, dilution range 1:50-1:500） and immunohistochemistry （including paraffin-embedded sections） （starting dilution 1:50, dilution range 1:50-1:500）.
Suitable for use as control antibody for VEGF siRNA （h）: sc-29520, VEGF siRNA （m）: sc-36815, VEGF shRNA Plasmid （h）: sc-29520-SH, VEGF shRNA Plasmid （m）: sc-36815-SH, VEGF shRNA （h） Lentiviral Particles: sc-29520-V and VEGF shRNA （m） Lentiviral Particles: sc-36815-V.
Molecular Weight of VEGF: 15 kDa.
Molecular Weight of GST-tagged VEGF: 40 kDa.
DATA
AB 97 K 65 K 48 K
< VEGF fusion 31 K
protein
22 K
VEGF （VG-1）: sc-53462. Western blot analysis of biologically active human recombinant VEGF （A） and mouse recombinant VEGF （B）.
SELECT PRODUCT CITATIONS
1. Economou, M.A. 2008. Uveal melanoma and macular degeneration: molecular biology and potential therapeutic applications. Acta Ophthalmol.
86: 930-931.
1 Economou, M.A., et al. 2008. Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin （PPP）, an inhibitor of the insulin-like growth factor-1 receptor. Acta Ophthalmol. 86 Thesis 4: 42-49.
2 Economou, M.A., et al. 2008. Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin （PPP）, an inhibitor of the Insulin-like growth factor-1 receptor. Invest. Ophthalmol. Vis. Sci. 49: 2620-2626.
3 Ma, J., et al. 2009. PTEN regulate angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol. Cell. Biochem. E-Published.
STORAGE
Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.
Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0